Niagen Bioscience マネジメント
マネジメント 基準チェック /24
Niagen Bioscienceの CEO はRob Friedで、 Jun2018年に任命され、 の在任期間は 8.17年です。 の年間総報酬は$ 8.38Mで、 7.7%給与と92.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の2.1%を直接所有しており、その価値は$ 5.25M 。経営陣と取締役会の平均在任期間はそれぞれ6.5年と9.3年です。
主要情報
Rob Fried
最高経営責任者
US$8.4m
報酬総額
| CEO給与比率 | 7.71% |
| CEO在任期間 | 8.2yrs |
| CEOの所有権 | 2.1% |
| 経営陣の平均在職期間 | 6.5yrs |
| 取締役会の平均在任期間 | 9.3yrs |
経営陣の近況
Recent updates
ナラティブ更新 • Jul 29
NAGE: Longevity And GLP-1 Wellness Tailwinds Will Support Future Upside
Niagen Bioscience's analyst price target has been updated from $18.00 to $21.20 as analysts factor in recent Street research that highlights both tempered near term expectations and longer term support from trends in longevity, GLP-1 adoption, and cellular wellness demand. Analyst Commentary Recent Street research on Niagen Bioscience shows a mix of trimmed targets and fresh positive views, with bullish analysts still highlighting long term themes in longevity, GLP-1 adoption, and cellular wellness as key supports for the stock's investment case.
ナラティブ更新 • Jul 14
NAGE: Rare Disease Drug Designations Will Drive Future Longevity Upside
Analysts have reset their fair value estimate for Niagen Bioscience to $9.00 from $12.00, reflecting updated views on revenue growth, profit margins, and the long term opportunity in ingredients tied to longevity and cellular wellness trends. Analyst Commentary Analyst views on Niagen Bioscience are mixed, with the new US$9.00 fair value estimate broadly aligned with a recent price target from one supportive firm, while several bearish analysts have trimmed their expectations.ナラティブ更新 • Jun 30
NAGE: Future Execution On Telehealth Platform Will Drive Upside Potential
Niagen Bioscience's analyst price target has been revised lower from $23.00 to $18.00 as analysts incorporate updated assumptions for revenue growth, profit margin, discount rate, and future P/E into their models. Analyst Commentary Bullish analysts following Niagen Bioscience are revisiting their models at a detailed level, adjusting assumptions for revenue growth, profit margins, discount rates, and future P/E multiples.
ナラティブ更新 • Jun 16
NAGE: Injectables And Expanded Clinical Access Will Support Future Buyback Upside
Niagen Bioscience's analyst price target has been reduced by a combined $5 across recent reports as analysts factor in updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples, while maintaining a fair value estimate of $12.60. Analyst Commentary Recent research on Niagen Bioscience highlights a mix of optimism about the company’s long term potential and caution around the assumptions that underpin the current fair value estimate of $12.60.ナラティブ更新 • Jun 02
NAGE: Core Demand And Injectables Will Support Future Buyback Driven Upside
Analysts have trimmed their average price target on Niagen Bioscience by $1 to $12.60, reflecting updated models that incorporate modest adjustments to discount rates, revenue growth, profit margin assumptions, and a slightly lower future P/E multiple. Analyst Commentary Recent Street research around Niagen Bioscience centers on how updated models reconcile the current share price with revised assumptions for growth, profitability, and valuation multiples.ナラティブ更新 • May 14
NAGE: Core Demand And Injectables Will Drive Future Upside Potential
Niagen Bioscience's analyst price target has shifted from $13.60 to $12.60, as analysts adjust their models to slightly lower revenue growth, profit margin, and fair value assumptions while still highlighting ongoing demand in the core business and potential upside from the injectable segment. Analyst Commentary Recent research updates show a consistent pattern of price target reductions, with the latest move taking the blended target to US$12.60.ナラティブ更新 • Apr 22
NAGE: Core Demand And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14, citing updated models after Q4 results that point to steady demand in the core business and possible upside from the injectable segment. Analyst Commentary Recent commentary around Niagen Bioscience centers on how updated Q4 models affect the risk and reward trade off, with attention on both the established core business and the injectable opportunity.ナラティブ更新 • Apr 07
NAGE: Core Strength And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14, citing updated models after Q4 results that reflect steady demand in the core business and possible upside from the injectable segment. Analyst Commentary Analysts see the updated price target as largely reflecting model clean up after Q4, rather than a shift in the overall view on the business.ナラティブ更新 • Mar 23
NAGE: Core Demand And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14. This reflects updated models after Q4 results that pointed to steady demand in the core business and potential upside from the injectable segment.ナラティブ更新 • Mar 06
NAGE: Core Demand And Injectables Outlook Will Support Future Upside
Analysts have trimmed their 12 month price target on Niagen Bioscience from $16.04 to $13.60, citing updated models that reflect steady demand in the core business, potential upside in injectables, adjustments to revenue growth and profit margin assumptions, and a lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to steady demand in the core business as a key support for current valuation, suggesting the updated models still see the existing portfolio as a meaningful earnings driver.Seeking Alpha • Nov 15
Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years
Summary Niagen Bioscience delivered record Q3 revenue, rising 33% year-over-year, driven by strong Tru Niagen demand and accelerating distribution partnerships. Gross margin expanded to 64.5%, while operating income and adjusted EBITDA grew sharply, reflecting improving scale and cost discipline. Cash from operations already exceeded last year’s total, supporting a new $10 million share repurchase program. The FDA’s reversal on NMN introduces meaningful uncertainty for future demand and competitive dynamics in the NAD+ category. Niagen Bioscience remains financially strong, but sustained momentum in a post-NMN market is unproven, warranting a hold rating. Read the full article on Seeking Alpha分析記事 • Nov 11
We Think Niagen Bioscience's (NASDAQ:NAGE) Profit Is Only A Baseline For What They Can Achieve
Even though Niagen Bioscience, Inc. ( NASDAQ:NAGE ) posted strong earnings, investors appeared to be underwhelmed. We...分析記事 • Nov 07
Niagen Bioscience, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Niagen Bioscience, Inc. ( NASDAQ:NAGE ) just released its quarterly report and things are looking bullish. The company...分析記事 • Oct 03
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 25% Cheaper Price Remains In Tune With Revenues
To the annoyance of some shareholders, Niagen Bioscience, Inc. ( NASDAQ:NAGE ) shares are down a considerable 25% in...ナラティブ更新 • Aug 08
Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects
Upward revisions to Niagen Bioscience's price target reflect positive clinical trial results confirming both safety and significant efficacy of its NAD+ supplementation, increased market confidence, and ongoing product and sales momentum, resulting in a higher consensus analyst price target rising from $14.90 to $15.84. Analyst Commentary Positive clinical study results published in a peer-reviewed journal demonstrated that Niagen Bioscience’s NAD+ supplementation is safe for patients with Werner syndrome and achieved a ~140% increase in blood NAD+ levels, along with improvements in liver, kidney, and arterial health markers.分析記事 • Aug 08
Niagen Bioscience, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
NasdaqCM:NAGE 1 Year Share Price vs Fair Value Explore Niagen Bioscience's Fair Values from the Community and select...分析記事 • Aug 06
What You Can Learn From Niagen Bioscience, Inc.'s (NASDAQ:NAGE) P/S After Its 28% Share Price Crash
NasdaqCM:NAGE 1 Year Share Price vs Fair Value Explore Niagen Bioscience's Fair Values from the Community and select...分析記事 • Jun 17
Market Participants Recognise Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Revenues Pushing Shares 29% Higher
Niagen Bioscience, Inc. ( NASDAQ:NAGE ) shares have continued their recent momentum with a 29% gain in the last month...分析記事 • May 10
Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
A week ago, Niagen Bioscience, Inc. ( NASDAQ:NAGE ) came out with a strong set of first-quarter numbers that could...分析記事 • Apr 05
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 30% Cheaper Price Remains In Tune With Revenues
The Niagen Bioscience, Inc. ( NASDAQ:NAGE ) share price has softened a substantial 30% over the previous 30 days...分析記事 • Mar 29
A Look At The Fair Value Of Niagen Bioscience, Inc. (NASDAQ:NAGE)
Key Insights Niagen Bioscience's estimated fair value is US$7.18 based on 2 Stage Free Cash Flow to Equity Niagen...
新しいナラティブ • Feb 09
NIAGEN IV Expansion And FDA Approvals Will Unlock Future Opportunities
Expansion in clinics and strategic partnerships support revenue growth through increased e-commerce and pharmaceutical-grade product sales.分析記事 • Nov 07
ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors
ChromaDex Corporation's ( NASDAQ:CDXC ) strong earnings report was rewarded with a positive stock price move. We did...分析記事 • Nov 05
Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%
Despite an already strong run, ChromaDex Corporation ( NASDAQ:CDXC ) shares have been powering on, with a gain of 70...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$16m |
| Mar 31 2026 | n/a | n/a | US$19m |
| Dec 31 2025 | US$8m | US$646k | US$17m |
| Sep 30 2025 | n/a | n/a | US$20m |
| Jun 30 2025 | n/a | n/a | US$18m |
| Mar 31 2025 | n/a | n/a | US$14m |
| Dec 31 2024 | US$1m | US$500k | US$9m |
| Sep 30 2024 | n/a | n/a | US$1m |
| Jun 30 2024 | n/a | n/a | -US$1m |
| Mar 31 2024 | n/a | n/a | -US$4m |
| Dec 31 2023 | US$1m | US$500k | -US$5m |
| Sep 30 2023 | n/a | n/a | -US$6m |
| Jun 30 2023 | n/a | n/a | -US$6m |
| Mar 31 2023 | n/a | n/a | -US$11m |
| Dec 31 2022 | US$1m | US$500k | -US$17m |
| Sep 30 2022 | n/a | n/a | -US$20m |
| Jun 30 2022 | n/a | n/a | -US$28m |
| Mar 31 2022 | n/a | n/a | -US$27m |
| Dec 31 2021 | US$1m | US$500k | -US$27m |
| Sep 30 2021 | n/a | n/a | -US$28m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$21m |
| Dec 31 2020 | US$1m | US$519k | -US$20m |
| Sep 30 2020 | n/a | n/a | -US$23m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$30m |
| Dec 31 2019 | US$2m | US$487k | -US$32m |
報酬と市場: Robの 総報酬 ($USD 8.38M ) は、 US市場 ($USD 1.59M ) の同規模の企業の平均を上回っています。
報酬と収益: Robの報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。
CEO
Rob Fried (66 yo)
8.2yrs
在職期間
US$8,381,900
報酬
Mr. Robert N. Fried, also known as Rob, has been the Chief Executive Officer of Niagen Bioscience, Inc. (formerly known as ChromaDex Corporation) since June 22, 2018 and its a Director since July 2015. Mr....
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder & Chairman | 26.5yrs | US$268.08k | 2.92% $ 7.3m | |
| CEO & Director | 8.2yrs | US$8.38m | 2.1% $ 5.3m | |
| CFO & Principal Accounting Officer | 1.8yrs | US$648.24k | 0.017% $ 43.6k | |
| Senior VP & General Counsel | 2.1yrs | US$558.01k | 0.0058% $ 14.4k | |
| Senior Vice President of Global Regulatory & Scientific Affairs | 6.5yrs | データなし | データなし | |
| Chief Marketing Officer | 1.8yrs | データなし | データなし | |
| Managing Director of Asia Pacific | 7.8yrs | データなし | データなし | |
| Head of Media Relations & Partnerships | no data | データなし | データなし | |
| Controller | no data | US$374.47k | 0% $ 0 | |
| Vice President of Finance | no data | データなし | データなし | |
| Assistant Controller | no data | データなし | データなし |
6.5yrs
平均在職期間
50yo
平均年齢
経験豊富な経営陣: NAGEの経営陣は経験豊富で経験豊富です（平均在職期間は6.5年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder & Chairman | 26.5yrs | US$268.08k | 2.92% $ 7.3m | |
| CEO & Director | 11.1yrs | US$8.38m | 2.1% $ 5.3m | |
| Member of Scientific Advisory Board | 9.2yrs | データなし | データなし | |
| Lead Independent Director | 9.4yrs | US$293.08k | 0.0088% $ 22.1k | |
| Chairman of the Scientific Advisory Board | 12.1yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 11.9yrs | データなし | データなし | |
| Independent Director | 4.3yrs | US$265.58k | 0% $ 0 | |
| Non-Executive Director | 9yrs | US$243.08k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$258.08k | 0% $ 0 | |
| Chief Scientific Advisor & Member of Scientific Advisory Board | 11.9yrs | データなし | データなし | |
| Member of the Scientific Advisory Board | 7.1yrs | データなし | データなし | |
| Non-Executive Director | 4.7yrs | US$245.58k | 0% $ 0 |
9.3yrs
平均在職期間
65yo
平均年齢
経験豊富なボード: NAGEの 取締役会 は 経験豊富 であると考えられます ( 9.3年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/21 04:30 |
| 終値 | 2026/08/21 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Niagen Bioscience, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9
| アナリスト | 機関 |
|---|---|
| Jeffrey Van Sinderen | B. Riley Securities, Inc. |
| Susan Anderson | Canaccord Genuity |
| Jeffrey Mark | Farmhouse Equity Research |